Skip to main content

Table 3 Multivariable association of A) QoL at last available follow-up and B) change in QoL between Baseline and last available follow-up and clinical characteristics with mortality

From: The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry

  SGRQ total EQ-5D VAS UCSD-SOBQ WHO-5
HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
A) Multivariable model including QoL at last available follow-up
 QoL at last available follow-up a 1.12 1.06; 1.18 < 0.001 0.91 0.87; 0.96 0.001 1.14 1.08; 1.20 < 0.001 0.83 0.69; 0.99 0.048
 Age a 1.32 1.14; 1.54 < 0.001 1.30 1.12; 1.51 0.001 1.27 1.09; 1.48 0.002 1.25 1.07; 1.46 0.006
 Number of comorbidities
  0 1.00    1.00    1.00    1.00   
  1 2.40 1.15; 5.01 0.02 1.93 0.98; 3.77 0.057 2.51 0.92; 6.81 0.071 2.03 0.93; 4.41 0.075
  2 2.10 1.02; 4.32 0.043 1.62 0.83; 3.19 0.161 2.40 0.90; 6.40 0.079 2.24 1.05; 4.80 0.038
  3 2.78 1.26; 6.09 0.011 2.15 1.02; 4.53 0.043 3.16 0.99; 10.05 0.052 2.31 0.97; 5.46 0.057
  4+ 1.95 0.69; 5.49 0.205 1.98 0.77; 5.07 0.155 1.30 0.29; 5.86 0.734 2.80 1.00; 7.86 0.051
 Change in FVC % predicted
  Stable/increase 1.00    1.00    1.00    1.00   
  Decrease by 0 to 10% 1.63 0.98; 2.71 0.058 1.60 0.97; 2.64 0.066 1.41 0.75; 2.64 0.286 1.75 1.01; 3.03 0.047
  Decrease by > 10% 2.34 1.18; 4.62 0.015 2.29 1.16; 4.51 0.017 2.14 0.87; 5.26 0.096 2.70 1.32; 5.53 0.007
 Hospitalisation 1.26 0.80; 1.97 0.322 1.54 0.98; 2.40 0.06 1.00 0.57; 1.74 0.994 1.29 0.81; 2.06 0.286
 Overall physician’s judgement of clinical course of IPF
  Stable disease 1.00    1.00    1.00    1.00   
  Slow progression 1.48 0.92; 2.38 0.106 1.70 1.08; 2.69 0.022 1.30 0.71; 2.37 0.399 1.91 1.16; 3.17 0.012
  Rapid progression 0.97 0.46; 2.04 0.933 1.18 0.55; 2.53 0.674 1.06 0.46; 2.42 0.896 1.25 0.53; 2.95 0.617
  No judgement possible 0.89 0.46; 1.74 0.743 0.98 0.52; 1.84 0.95 1.26 0.54; 2.93 0.588 0.94 0.47; 1.91 0.871
B) Multivariable model including change in QoL between baseline and last available follow-up
 Change in QoL between baseline and last available follow-up a 1.05 0.98; 1.13 0.148 0.97 0.91; 1.04 0.364 1.07 0.98; 1.16 0.127 0.85 0.68; 1.07 0.165
 Age a 1.30 1.11; 1.52 0.001 1.31 1.12; 1.53 0.001 1.26 1.02; 1.56 0.031 1.26 1.07; 1.48 0.006
 Number of comorbidities
  0 1.00    1.00    1.00    1.00   
  1 1.98 0.97; 4.04 0.061 1.83 0.92; 3.63 0.084 2.03 0.71; 5.84 0.187 1.93 0.89; 4.20 0.096
  2 1.85 0.90; 3.79 0.092 1.70 0.85; 3.40 0.135 2.01 0.65; 6.21 0.226 2.14 0.99; 4.63 0.054
  3 2.40 1.10; 5.24 0.028 2.25 1.06; 4.76 0.035 3.68 1.17; 11.55 0.026 2.18 0.91; 5.23 0.082
  4+ 2.04 0.75; 5.57 0.165 2.27 0.87; 5.92 0.093 1.54 0.26; 9.06 0.634 2.99 1.09; 8.22 0.034
 Change in FVC % predicted
  Stable/increase 1.00    1.00    1.00    1.00   
  Decrease by 0 to 10% 1.69 1.02; 2.82 0.044 1.65 0.99; 2.76 0.055 1.11 0.57; 2.14 0.762 1.67 0.95; 2.91 0.073
  Decrease by > 10% 2.16 1.08; 4.31 0.029 2.26 1.14; 4.50 0.02 1.72 0.71; 4.14 0.227 2.43 1.18; 5.00 0.015
 Hospitalisation 1.35 0.85; 2.13 0.202 1.54 0.98; 2.42 0.059 1.30 0.68; 2.45 0.427 1.30 0.81; 2.08 0.285
 Overall physician’s judgement of clinical course of IPF
  Stable disease 1.00    1.00    1.00    1.00   
  Slow progression 1.69 1.05; 2.73 0.03 1.83 1.14; 2.94 0.012 1.38 0.67; 2.85 0.381 1.89 1.15; 3.12 0.013
  Rapid progression 1.42 0.69; 2.91 0.341 1.63 0.76; 3.46 0.207 1.27 0.47; 3.41 0.636 1.38 0.61; 3.12 0.439
  No judgement possible 0.97 0.49; 1.92 0.922 0.96 0.50; 1.83 0.902 1.24 0.52; 2.95 0.622 0.83 0.39; 1.77 0.635
  1. CI confidence interval, EQ-5D VAS EuroQol five-dimensional questionnaire, recorded as a visual analog scale, HR hazard ratio, FVC forced vital capacity, IPF idiopathic pulmonary fibrosis, QoL quality of life, SD standard deviation, SGRQ St. George’s Respiratory Questionnaire, USCD-SOBQ University of California San Diego Shortness of Breath Questionnaire, WHO-5 World Health Organization-5 Well-Being Index
  2. a HR for increase by 5 points on the QoL scale or by 5 years of age